clot-dissolving drug


Also found in: Encyclopedia.

clot-dissolving drug

Thrombolytic (agent), see there.
References in periodicals archive ?
Note the delay in incorporating tPA into standard practice whereby 14 years after FDA approval, less than 7% of stroke patients received this clot-dissolving drug in community hospitals.
Better option In one of several studies, stroke patients randomly assigned to get a clot-removal procedure in addition to a standard clot-dissolving drug (tPA) did better three months later than those treated with the drug alone.
Silver recommended the use of tPA, a clot-dissolving drug manufactured by Genentec, Inc, as the only U.S.
Researchers at Genentech, South San Francisco, used SAS/PH to assemble a CANDA for clinical trial data of a clot-dissolving drug administered to more than 40,000 patients.
* Under pressure to bring its blood clot-dissolving drug (known as tissue plasminogen activator, or TPA) to market before a competitor released a cheaper product, the biotechnology firm Genentech funded a major effort in conjunction with the NIH in which several laboratories studied the drug.
IAT uses a catheter to deliver a clot-dissolving drug to the location of the clot in the brain artery or physically remove the clot particles and allow blood flow to resume.
Fortunately, he was at one of the few hospitals at the time who were "allowed" to provide this clot-dissolving drug to consenting patients.
"Occasionally, atherectomy (minimally invasive removal of plaque) or thrombolytic therapy (injection of a clot-dissolving drug into the artery) are appropriate treatment options.
During the study, the researchers treated 37 patients with the clot-dissolving drug called tPA, while using ultrasound to loosen the proteins in their blood clots and send the drug into the clots faster.
The only other treatment currently approved by the Food & Drug Administration (FDA) for acute ischemic stroke is a clot-dissolving drug called tissue plasminogen activator (tPA).
Most strokes result from clots, but only about 1 in 20 patients receives the sole clot-dissolving drug approved for treating stroke, tissue plasminogen activator (tPA).
In June the Food and Drug Administration (FDA) approved alteplase, a clot-dissolving drug also referred to as a tissue plasminogen activator.